Medipharm Financial Statements From 2010 to 2024

LABS Stock  CAD 0.07  0.01  7.14%   
Medipharm Labs financial statements provide useful quarterly and yearly information to potential Medipharm Labs Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Medipharm Labs financial statements helps investors assess Medipharm Labs' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Medipharm Labs' valuation are summarized below:
Gross Profit
-13.4 M
Profit Margin
(0.35)
Market Capitalization
26.7 M
Enterprise Value Revenue
0.3658
Revenue
37.8 M
We have found one hundred twenty available fundamental ratios for Medipharm Labs, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Medipharm Labs' last-minute fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 28th of November 2024, Market Cap is likely to drop to about 22.4 M. In addition to that, Enterprise Value is likely to drop to about 7.5 M

Medipharm Labs Total Revenue

39.66 Million

Check Medipharm Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Medipharm Labs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Interest Expense of 346.8 K or Selling General Administrative of 14.7 M, as well as many indicators such as Price To Sales Ratio of 0.68, Dividend Yield of 0.0 or PTB Ratio of 0.42. Medipharm financial statements analysis is a perfect complement when working with Medipharm Labs Valuation or Volatility modules.
  
This module can also supplement various Medipharm Labs Technical models . Check out the analysis of Medipharm Labs Correlation against competitors.

Medipharm Labs Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets75.9 M63.9 M42 M
Slightly volatile
Short and Long Term Debt Total2.2 M2.3 M2.8 M
Slightly volatile
Other Current Liabilities4.6 M6.4 M2.6 M
Slightly volatile
Total Current Liabilities13.7 M10.9 M7.6 M
Slightly volatile
Total Stockholder Equity59.2 M53 M32.7 M
Slightly volatile
Net Tangible Assets59.3 M95.6 M37.5 M
Slightly volatile
Accounts Payable4.2 M2.1 M3.1 M
Slightly volatile
Cash19.7 M18 M11 M
Slightly volatile
Cash And Short Term Investments19.7 M18 M11 M
Slightly volatile
Common Stock Shares Outstanding381.5 M363.3 M109.1 M
Slightly volatile
Liabilities And Stockholders Equity75.9 M63.9 M42 M
Slightly volatile
Total Liabilities17.1 M10.9 M9.5 M
Slightly volatile
Total Current Assets52 M36.6 M28.8 M
Slightly volatile
Accumulated Other Comprehensive Income15.8 M29.5 M8.8 M
Slightly volatile
Short Term Debt2.7 M2.2 M1.5 M
Slightly volatile
Common Stock120.7 M200.2 M66.6 M
Slightly volatile
Property Plant And Equipment Net25.4 M25.3 M13.5 M
Slightly volatile
Non Current Assets Total27.7 M27.3 M14.6 M
Slightly volatile
Common Stock Total Equity167.2 M159.3 M57.9 M
Slightly volatile
Short Term Investments251.8 K265 K359.2 K
Slightly volatile
Other Current Assets2.5 M2.9 M1.5 M
Slightly volatile
Net Invested Capital73.3 M55.1 M36.2 M
Slightly volatile
Cash And Equivalents22.9 M27.8 M11.9 M
Slightly volatile
Net Working Capital44.1 M25.8 M21.8 M
Slightly volatile
Property Plant Equipment25 M20.8 M13.2 M
Slightly volatile
Current Deferred Revenue106.4 K112 K354.4 K
Slightly volatile
Net Receivables5.6 M5.9 M10.8 M
Slightly volatile
Capital Surpluse65.9 K74.2 K80.8 K
Slightly volatile
Inventory14.9 M9.9 M13.5 M
Pretty Stable
Property Plant And Equipment Gross43.5 M52.3 M26.2 M
Slightly volatile
Short and Long Term Debt2.8 M2.1 M4.6 M
Slightly volatile
Capital Stock154.7 M200.2 M66.9 M
Slightly volatile
Capital Lease Obligations329.8 K190 K762.4 K
Slightly volatile
Other Liabilities200.9 K211.5 K3.6 M
Slightly volatile
Intangible Assets1.1 MM313.8 K
Slightly volatile

Medipharm Labs Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.6 M2.5 M2.1 M
Slightly volatile
Selling General Administrative14.7 M21.6 M9.1 M
Slightly volatile
Selling And Marketing Expenses3.2 M3.2 M1.8 M
Slightly volatile
Other Operating Expenses57.2 M51.9 M31.6 M
Slightly volatile
Total Operating Expenses18.8 M23.1 M11.6 M
Slightly volatile
Interest Income798 K840 K1.1 M
Slightly volatile
Research Development198.6 K209 K547 K
Slightly volatile
Cost Of Revenue35 M28.8 M23.1 M
Slightly volatile
Reconciled Depreciation4.6 M2.5 M2.5 M
Slightly volatile

Medipharm Labs Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow17.5 M24.1 M9.7 M
Slightly volatile
Depreciation3.8 M2.5 M2.5 M
Slightly volatile
Capital Expenditures447.4 K471 K4.9 M
Very volatile
End Period Cash Flow20 M18 M11.1 M
Slightly volatile
Change To Netincome8.1 M16.2 M5.8 M
Slightly volatile
Stock Based Compensation3.2 MM2.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.680.714313.702
Slightly volatile
PTB Ratio0.420.445519.295
Slightly volatile
Days Sales Outstanding61.5264.7598204
Slightly volatile
Stock Based Compensation To Revenue0.120.06130.1567
Slightly volatile
Capex To Depreciation0.180.18729.8579
Slightly volatile
PB Ratio0.420.445519.295
Slightly volatile
Inventory Turnover2.022.74851.4986
Slightly volatile
Days Of Inventory On Hand225133391
Slightly volatile
Payables Turnover6.8912.77324.3182
Slightly volatile
Sales General And Administrative To Revenue0.50.65440.5766
Slightly volatile
Research And Ddevelopement To Revenue0.0060.00630.0279
Very volatile
Capex To Revenue0.01350.01420.8948
Slightly volatile
Cash Per Share0.04770.05020.1108
Pretty Stable
Days Payables Outstanding27.1528.5754297
Slightly volatile
Intangibles To Total Assets0.01690.01610.0037
Slightly volatile
Current Ratio3.083.37232.4329
Slightly volatile
Receivables Turnover5.925.63622.3209
Slightly volatile
Graham Number0.330.34380.7785
Pretty Stable
Shareholders Equity Per Share0.140.14590.2575
Slightly volatile
Debt To Equity0.03770.03970.1093
Slightly volatile
Capex Per Share0.00120.00130.2501
Slightly volatile
Revenue Per Share0.08640.0910.1996
Very volatile
Interest Debt Per Share0.00650.00680.0399
Pretty Stable
Debt To Assets0.03130.03290.0822
Slightly volatile
Operating Cycle188198588
Slightly volatile
Price Book Value Ratio0.420.445519.295
Slightly volatile
Days Of Payables Outstanding27.1528.5754297
Slightly volatile
Ebt Per Ebit1.090.73191.0252
Slightly volatile
Company Equity Multiplier1.421.20621.2871
Pretty Stable
Long Term Debt To Capitalization0.07060.110.0745
Slightly volatile
Total Debt To Capitalization0.03630.03820.0952
Slightly volatile
Debt Equity Ratio0.03770.03970.1093
Slightly volatile
Quick Ratio2.462.4611.9294
Slightly volatile
Net Income Per E B T0.70.97930.9154
Pretty Stable
Cash Ratio2.271.65531.3399
Slightly volatile
Cash Conversion Cycle311169301
Slightly volatile
Days Of Inventory Outstanding225133391
Slightly volatile
Days Of Sales Outstanding61.5264.7598204
Slightly volatile
Price To Book Ratio0.420.445519.295
Slightly volatile
Fixed Asset Turnover1.511.30821.0375
Slightly volatile
Debt Ratio0.03130.03290.0822
Slightly volatile
Price Sales Ratio0.680.714313.702
Slightly volatile
Asset Turnover0.320.51710.3085
Slightly volatile
Price Fair Value0.420.445519.295
Slightly volatile

Medipharm Labs Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap22.4 M23.6 M176.1 M
Slightly volatile

Medipharm Fundamental Market Drivers

Forward Price Earnings27.4725
Cash And Short Term Investments18 M

About Medipharm Labs Financial Statements

Medipharm Labs investors utilize fundamental indicators, such as revenue or net income, to predict how Medipharm Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue112 K106.4 K
Total Revenue33.1 M39.7 M
Cost Of Revenue28.8 M35 M
Stock Based Compensation To Revenue 0.06  0.12 
Sales General And Administrative To Revenue 0.65  0.50 
Research And Ddevelopement To Revenue 0.01  0.01 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.09  0.09 
Ebit Per Revenue(0.55)(0.58)

Pair Trading with Medipharm Labs

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medipharm Labs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medipharm Labs will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Medipharm Labs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medipharm Labs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medipharm Labs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medipharm Labs Corp to buy it.
The correlation of Medipharm Labs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medipharm Labs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medipharm Labs Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medipharm Labs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Medipharm Stock

Medipharm Labs financial ratios help investors to determine whether Medipharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medipharm with respect to the benefits of owning Medipharm Labs security.